| |
Doxorubicin
|
Cisplatin
|
---|
Cell type
|
Mean IC50 (uM)
|
Fold change
|
Mean IC50 (uM)
|
Fold change
|
---|
MS206-2
|
Adherent
|
0.062 ± 0.01
|
28.8^
|
4.38 ± 0.98
|
5.7^
|
AI
|
1.79 ± 0.4
|
25.2 ± 6.9
|
143B
|
Adherent
|
0.025 ± 0.01
|
13*
|
1.97 ± 0.19
|
1.9*
|
AI
|
0.31 ± 0.1
|
3.12 ± 0.10
|
mHOS
|
Adherent
|
0.085 ± 0.013
|
35*
|
3.10 ± 0.53
|
6.9*
|
AI
|
2.97 ± 1.9
|
21.4 ± 10.
|
MG-63
|
Adherent
|
0.13 ± 0.06
|
>75#
|
2.68 ± 1.6
|
6.2*
|
AI
|
>50% survival
|
16.9 ± 5.4
|
- ^Indicates p < 0.05 (two-tailed two-sample t-test).
- *Indicates p < 0.05 (wilcoxon signed-rank test).
- #Indicates >50% cell viability after treatment, so we could not calculate an IC50.